US food industry concentration and health policy

A small group of multinational food corporations dominate the U.S. market, using loosely regulated terms such as “natural” and “healthy” to label products—a practice described as health‑washing. This concentration raises concerns about consumer deception, food‑borne‑illness risk, and the erosion of trust when familiar brands change formulations without clear communication.

At the same time, these firms are confronting a wave of litigation aimed at blocking public‑health initiatives, including stricter nutrition labeling, sugary‑drink taxes, and tighter nutrient standards. An investigation documented hundreds of lawsuits filed by major companies such as Coca‑Cola, PepsiCo, Danone, and Mars.

Compounding the pressure, the rapid uptake of GLP‑1 receptor agonist drugs (e.g., Ozempic, Wegovy, Mounjaro) is reshaping U.S. consumer spending. The appetite‑suppressing effects of these medications have reduced demand for high‑sugar and high‑fat foods by a few percent while boosting purchases of healthier items. This shift is creating new export opportunities for producers outside the United States, notably Italian food manufacturers seeking to meet the emerging demand for healthier products.